



## COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

### Monthly Report of Application Procedures, Guidelines and Related Documents

The CVMP Monthly Report includes statistical data for the current and previous two years on Scientific Advice, Initial Evaluations, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

#### Applications for Medicinal Products for Veterinary Use and Maximum Residue Limits (MRLs)

Scientific Advice Requests					
	95-06	2007	2008	2009	Total
Submitted	51	7	5	4	67

Initial Evaluation					
	95-06	2007	2008	2009	Total
Full <sup>1</sup>	83	14	13	5	115
Abridged/Generics	6	1	3	0	10
Withdrawals	11	0	1	0	12
Positive Opinions	69	9	13	8	99
Negative Opinions	1	0	0	0	1

Marketing Authorisations					
	95-06	2007	2008	2009	Total
Granted	66	9	13	8	96
Withdrawals	1	0	1	0	2
Not renewed	1	1	0	0	2

<sup>1</sup> Initial applications submitted and validated: 125 applications in total (full + abridged), comprising 65 immunologicals and 60 pharmaceuticals. Negative opinions: in case of appeals, the opinion will not be counted twice.

Extensions - Annex II Applications <sup>2</sup>					
	95-06	2007	2008	2009	Total
Submitted	47	9	4	8	68
Withdrawals	1	0	1	1	3
Positive Opinions	32	1	7	1	41
Negative Opinions	0	0	0	0	0

Variations – Applications submitted					
	95-06	2007	2008	2009	Total
Type IA	238	29	23	19	375
Type IB		24	25	17	
Type II	111	47	52	17	225
Transfers	7	2	2	1	12

<sup>2</sup> Extensions applications submitted and validated: 58 line extensions in total, comprising 11 immunologicals and 47 pharmaceuticals; one opinion can cover a number of extensions

Renewals					
	95-06	2007	2008	2009	Total
Submitted	29	14	7	6	56
Positive Opinions	29	11	8	5	53
Negative Opinions	0	0	0	0	0

Establishment of MRLs for new substances					
	95-06	2007	2008	2009	Total
Submitted	63	2	1	2	68
Withdrawals	5	0	0	0	5
Positive Opinions <sup>3</sup>	49	3	2	1	55
Negative Opinions <sup>4</sup>	6	0	1	0	7

Arbitrations and Community Referrals					
	95-06	2007	2008	2009	Total
Referrals Submitted	21	6	11	8	46
Opinions Reached	4	10	6	5	25

Extensions / Modifications/Extrapolations of MRLs					
	95-06	2007	2008	2009	Total
Submitted	95	1	2	2	100
Withdrawals	4	0	0	0	4
Positive Opinions <sup>3</sup>	107	4	2	2	115
Negative Opinions <sup>4</sup>	6	0	0	0	6
Extrapolations	45	0	5	0	50

<sup>3</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits

<sup>4</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

### CVMP Opinions in 2009 on Medicinal Products for Veterinary Use

#### Positive Opinions

Product	Marketing authorisation holder	Therapeutic area	EMEA/CVMP	European Commission
			Validation	Opinion received
<ul style="list-style-type: none"> <li>▪ Brand name</li> <li>▪ INN</li> </ul>		<ul style="list-style-type: none"> <li>▪ Target species</li> <li>▪ Summary of indication</li> </ul>	<ul style="list-style-type: none"> <li>▪ Opinion</li> <li>▪ Active time</li> <li>▪ Clock stop</li> </ul>	<ul style="list-style-type: none"> <li>▪ Date of decision</li> <li>▪ Notification</li> <li>▪ Official Journal</li> </ul>
<ul style="list-style-type: none"> <li>• Netvax</li> </ul>	Schering-Plough, UK	<ul style="list-style-type: none"> <li>• Chickens</li> <li>• Necrotic enteritis</li> </ul>	<ul style="list-style-type: none"> <li>• 10/02/2007</li> <li>• 11/02/2009</li> <li>• 210</li> <li>• 379</li> </ul>	<ul style="list-style-type: none"> <li>• 16/03/2009</li> <li>• 16/04/2009</li> </ul>
<ul style="list-style-type: none"> <li>• BTVPUR Alsap 8</li> <li>• Inactivated adjuvanted vaccine</li> </ul>	Merial, France	<ul style="list-style-type: none"> <li>• Sheep, cattle</li> <li>• Prevention of Blue Tongue virus serotype 8</li> </ul>	<ul style="list-style-type: none"> <li>• 25/03/2008</li> <li>• 11/02/2009</li> <li>• 175</li> <li>• 149</li> </ul>	<ul style="list-style-type: none"> <li>• 12/02/2009</li> <li>• 17/03/2009</li> </ul>
<ul style="list-style-type: none"> <li>• Improvac</li> <li>• GnRF analogue</li> </ul>	<ul style="list-style-type: none"> <li>• Pfizer, UK</li> </ul>	<ul style="list-style-type: none"> <li>• Male pigs</li> <li>• Control of boar taint</li> </ul>	<ul style="list-style-type: none"> <li>• 14/08/2007</li> <li>• 11/03/2009</li> <li>• 210</li> <li>• 365</li> </ul>	<ul style="list-style-type: none"> <li>• 08/04/2009</li> <li>• 11/05/2009</li> </ul>
<ul style="list-style-type: none"> <li>• Leucofeligen FeLV/RCP</li> </ul>	<ul style="list-style-type: none"> <li>• Virbac, France</li> </ul>	<ul style="list-style-type: none"> <li>• Cats</li> <li>• Immunisation against against feline calicivirus, viral rhinotracheitis, panleucopenia ad leukaemia</li> </ul>	<ul style="list-style-type: none"> <li>• 18/03/2008</li> <li>• 11/03/2009</li> <li>• 210</li> <li>• 147</li> </ul>	<ul style="list-style-type: none"> <li>•</li> </ul>

<ul style="list-style-type: none"> <li>Leucogen</li> </ul>	<ul style="list-style-type: none"> <li>Virbac, France</li> </ul>	<ul style="list-style-type: none"> <li>Cats</li> <li>Immunisation against feline leukaemia</li> </ul>	<ul style="list-style-type: none"> <li>18/03/2008</li> <li>11/03/2008</li> <li>210</li> <li>147</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
<ul style="list-style-type: none"> <li>Melovem</li> <li>Meloxicam</li> </ul>	<ul style="list-style-type: none"> <li>Dopharma, NL</li> </ul>	<ul style="list-style-type: none"> <li>Cattle, pigs</li> <li>Musculo-skeletal</li> </ul>	<ul style="list-style-type: none"> <li>15/07/2008</li> <li>13/05/2009</li> <li>155</li> <li>119</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
<ul style="list-style-type: none"> <li>Suvaxyn PCV</li> <li>Porcine circovirus</li> </ul>	<ul style="list-style-type: none"> <li>Fort Dodge</li> <li>UK</li> </ul>	<ul style="list-style-type: none"> <li>Piglets</li> <li>Vaccine to reduce PCV-2 viraemia</li> </ul>	<ul style="list-style-type: none"> <li>20/05/2008</li> <li>13/05/2008</li> <li>184</li> <li>147</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>
<ul style="list-style-type: none"> <li>Palladia</li> </ul>	<ul style="list-style-type: none"> <li>Pfizer</li> <li>UK</li> </ul>	<ul style="list-style-type: none"> <li>Dogs</li> <li>Treatment of Patnaik grade II or III, recurrent, cutaneous tumours</li> </ul>	<ul style="list-style-type: none"> <li>20/05/2008</li> <li>18/06/2009</li> <li>174</li> <li>157</li> </ul>	<ul style="list-style-type: none"> <li></li> </ul>

#### Negative Opinions

<b>Product</b>	<b>Marketing authorisation holder</b>	<b>Therapeutic area</b>	<b>EMEA/CVMP</b>	<b>European Commission</b>
<ul style="list-style-type: none"> <li>Brand name</li> <li>INN</li> </ul>		<ul style="list-style-type: none"> <li>Target species</li> <li>Summary of indication</li> </ul>	<ul style="list-style-type: none"> <li>Validation</li> <li>Opinion</li> <li>Active time</li> <li>Clock stop</li> </ul>	<ul style="list-style-type: none"> <li>Opinion received</li> <li>Date of decision</li> <li>Notification</li> <li>Official Journal</li> </ul>

#### Withdrawals prior to opinion

<b>Product</b>	<b>Marketing authorisation holder</b>	<b>Therapeutic area</b>	<b>EMEA/CVMP</b>	<b>European Commission</b>
<ul style="list-style-type: none"> <li>Brand name</li> <li>INN</li> </ul>		<ul style="list-style-type: none"> <li>Target species</li> <li>Summary of indication</li> </ul>	<ul style="list-style-type: none"> <li>Validation</li> <li>Opinion</li> <li>Active time</li> <li>Clock stop</li> </ul>	<ul style="list-style-type: none"> <li>Opinion received</li> <li>Date of decision</li> <li>Notification</li> <li>Official Journal</li> </ul>

### CVMP Opinions in 2009 on establishment of MRLs for new substances

#### Positive Opinions

<b>Substance INN</b>	<b>Therapeutic area</b>	<b>EMEA/CVMP</b>	<b>European Commission</b>
	<ul style="list-style-type: none"> <li>Target species</li> </ul>	<ul style="list-style-type: none"> <li>Validation</li> <li>Opinion</li> <li>Active time</li> <li>Clock stop</li> </ul>	<ul style="list-style-type: none"> <li>Opinion received</li> <li>Date of regulation</li> <li>Official Journal</li> </ul>

#### Negative Opinions (Recommendation for inclusion in Annex IV or inability to recommend inclusion in any of the Annexes to Regulation 2377/90)

<b>Substance INN</b>	<b>Therapeutic area</b>	<b>EMEA/CVMP</b>	<b>European Commission</b>
	<ul style="list-style-type: none"> <li>Target species</li> </ul>	<ul style="list-style-type: none"> <li>Validation</li> <li>Opinion</li> <li>Active time</li> <li>Clock stop</li> </ul>	<ul style="list-style-type: none"> <li>Opinion received</li> <li>Date of regulation</li> <li>Official Journal</li> </ul>

### Arbitrations and Community Referrals in 2009

Type of referral	Date of clock start / CVMP opinion	<ul style="list-style-type: none"> <li>▪ Product name</li> <li>▪ INN</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	13/05/2008 15/01/2009	<ul style="list-style-type: none"> <li>▪ ENRO-K 10% oral solution</li> <li>▪ Enrofloxacin</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	13/05/2008 15/01/2009	<ul style="list-style-type: none"> <li>▪ Unisol (avifox) 10% oral solution</li> <li>▪ Enrofloxacin</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	14/08/2008 11/03/2009 (after re-examination)	<ul style="list-style-type: none"> <li>▪ Pharmsin 100% w/w water soluble granules</li> <li>▪ Tylosine tartrate</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	15/04/2009 (re-examination) 05/06/2009 (after re-examination)	<ul style="list-style-type: none"> <li>▪ Injectable veterinary medicinal products containing ivermectin indicated for use in cattle</li> <li>▪ Ivermectin</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	11/02/2009 (clock start)	<ul style="list-style-type: none"> <li>▪ All strengths of water soluble powders and oral solutions containing doxycycline hyclate</li> <li>▪ Doxycycline hyclate</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	16/04/2009 (clock start)	<ul style="list-style-type: none"> <li>▪ Veterinary medicinal formulations containing colistin at 2 MIU/ml and intended for administration in drinking water to any food producing species</li> <li>▪ Colistin sulfate</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	16/09/2008 13/05/2009 (under re-examination)	<ul style="list-style-type: none"> <li>▪ Clavobay Lactating Cow</li> <li>▪ Amoxicillin and clavulanic acid</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	16/09/2008 13/05/2009	<ul style="list-style-type: none"> <li>▪ Shotaflor 300 mg/ml</li> <li>▪ Florfenicol</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	16/09/2008 13/05/2009	<ul style="list-style-type: none"> <li>▪ Fenflor 300 mg/ml</li> <li>▪ Florfenicol</li> </ul>
Referral for arbitration – Art. 34(1) Directive 2001/82/EC	16/09/2008 13/05/2009	<ul style="list-style-type: none"> <li>▪ Pulmotil AC and associated names</li> <li>▪ Tilmicosin</li> </ul>
Referral for arbitration – Art. 34(1) Directive 2001/82/EC	16/07/2008 13/05/2009	<ul style="list-style-type: none"> <li>▪ Pulmotil 40/100/200 VET Premix</li> <li>▪ Tilmicosin</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	13/05/2009 (clock start)	<ul style="list-style-type: none"> <li>▪ Veterinary medicinal products containing quinolones or fluoroquinolones for all food-producing species</li> <li>▪ Quinolones / fluoroquinolones</li> </ul>
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	12/05/2009 (clock start)	<ul style="list-style-type: none"> <li>▪ Cevazuril 50 mg/ml oral suspension for piglets</li> <li>▪ Toltrazuril</li> </ul>

## Urgent procedures

Type of procedure	CVMP opinion	Product name

## Guidelines and Working Documents in 2009

### CVMP Efficacy

Reference number	Document title	Status
EMEA/ CVMP/016/00-Rev.1-CONSULTATION	Guideline on the conduct of bioequivalence studies for veterinary medicinal products	Adopted for consultation, March 2009  (End of consultation: September 2009)
EMEA/ CVMP/EWP/82829/2009	Question and Answer document in relation to CVMP Guideline on "Testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats"	Adopted, March 2009
EMEA/ CVMP/28510/2008	Guideline on dossier requirements for anticancer medicinal products for dogs and cats	Adopted, April 2009
EMEA/ CVMP/EWP/37388/2009-CONSULTATION	Concept paper on the revision of the guideline on statistical principles for veterinary clinical trials	Adopted for consultation, June 2009  (End of consultation: September 2009)

### CVMP Environmental Risk Assessment (ERA)

Reference number	Document title	Status
EMEA/ CVMP/ERA/10043/2009-CONSULTATION	Concept paper on the fate of veterinary medicinal products in manure	Adopted, April 2009

### CVMP Immunologicals

Reference number	Document title	Status
EMEA/ CVMP/IWP/105506/2007-CONSULTATION	Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza, bluetongue and foot-and-mouth disease	Adopted for consultation, March 2009  (End of consultation: September 2009)
EMEA/ CVMP/IWP/439467/2007-CONSULTATION	Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals	Adopted for consultation, March 2009  (End of consultation: September 2009)
EMEA/ CVMP/IWP/250147/2008-CONSULTATION	Guideline on data requirements to support in-use stability claims for veterinary vaccines	Adopted for consultation, March 2009  (End of consultation: September 2009)

EMEA/CVMP/IWP/123243/2006-Rev.1-CONSULTATION	Guideline on data requirements for immunological veterinary medicinal products intended for Minor Use or Minor Species/ Limited markets	Adopted for consultation, March 2009  (End of consultation: June 2009)
EMEA/CVMP/340494/2009	Question and Answer document on inactivation kinetics studies	Adopted, June 2009

### CVMP Pharmacovigilance

Reference number	Document title	Status
SOP-EMEA/599270/2007	SOP on Handling of pharmacovigilance Rapid Alerts (RAs) and Non Urgent Informaion (NUI)for veterinary use	Endorsed, January 2009
EMEA/CVMP/10418/2009	Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products	Adopted, February 2009
SOP/V/4023-Rev.1	Management of Period Safety Update Reports (PSURs) for Centrally Authorised Products (CAPs) and Annex I – Contact details of national competent authorities for PSUR submission	Adopted, April 2009
EMEA/CVMP/PhVWP/133883/2004-Rev.2	Mandate, Objectives and Rules of Procedure For The CVMP Pharmacovigilance Working Party (PhVWP-V)	Adopted, April 2009
EMEA/INS/PhV/85061/2008	Procedure for Reporting of Pharmacovigilance Inspections Requested by the CVMP	Adopted, April 2009
EMEA/CVMP/10418/2009-Rev.1	Combined VeDDRA List of Clinical Terms for Reporting Suspected Adverse Reactions in Animals and Humans	Adopted, June 2009
EMEA/CVMP/553/03-Rev.4	Revised List of Species and Breeds for Electronic Reporting of Suspected Adverse Reactions in Veterinary Pharmacovigilance	Adopted, June 2009
EMEA/CVMP/353015/2009	Deprecated Veddra Recoded Term List for Implementation of the Combined VeDDRA List	Adopted, June 2009

### Joint CHMP/CVMP Quality

Reference number	Document title	Status
EMEA/CVMP/QWP/544461/2007	Guideline on the quality aspects of single-dose veterinary spot-on products	Adopted, January 2009
EMEA/CHMP/CVMP/QWP/66309 3/2008	Question and Answer document on Plastic Immediate Packaging Materials	Adopted, January 2009

EMEA/CHMP/CVMP/QWP/17760/2009-Rev.1-CONSULTATION	Revised Guideline on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations	Adopted for consultation, February 2009  (End of consultation: August 2009)
EMEA/555991/2007	New Question and Answers which aim to clarify several issues associated with the use of Process Analytical Technology (PAT),	Adopted, February 2009
EMEA/CHMP/CVMP/QWP/160263/2009	Question and Answer documents on endotoxin/sterility testing during and at the end of shelf-life	Adopted, April 2009
EMEA/CHMP/CVMP/QWP/450653/2006	Recommendation on the Assessment of the quality of medicinal products containing existing/ known active substances	Adopted, April 2009

### CVMP Safety

Reference number	Document title	Status
EMEA/CVMP/SWP/322484/2008-Rev.1-CONSULTATION	Guideline on user safety for pharmaceutical veterinary medicinal products	Adopted for consultation, April 2009  (End of consultation, August 2009)
EMEA/CVMP/VICH/486/02-Rev.2	VICH Guideline on Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing	

### CVMP Scientific Advisory Group on Antimicrobials

Reference number	Document title	Status
EMEA/CVMP/SAGAM/81730/2006	Revised Reflection Paper on the use of 3rd and 4th generation cephalosporins in food producing animals in the European Union: development of resistance and impact on human and animal health, including recommendations	Adopted, March 2009
EMEA/CVMP/SAGAM/68290/2009	Reflection paper on MRSA in food producing and companion animals in the European Union: epidemiology and control options for human and animal health	Adopted, March 2009
EMEA/CVMP/SAGAM/113420/2009-CONSULTATION	Concept paper on the use of macrolides, lincosamides and streptogramins in food-producing animals in the European Union: development of resistance and impact on human and animal health	Adopted for consultation, June 2009  (End of consultation, August 2009)

## CVMP General

Reference number	Document title	Status
EMEA/INS/GCP/390778/2008	Procedure for the preparation of a risk-based programme for routine PhV Inspections of MAHs connected with Veterinary Centrally Authorised Products (CAPs)	Adopted, January 2009
EMEA/INS/GCP/85059/2008	Procedure for coordination of pharmacovigilance inspections requests by the CVMP	Adopted, January 2009
EMEA/INS/S&T/75010/2009	Sampling and Testing of Centrally Authorised products	Adopted, April 2009
EMEA/CVMP/248499/2007-Rev.1	Recommendation on the evaluation of the benefit-risk balance of veterinary medicinal products	Adopted, April 2009
EMEA/CVMP/425558/2006-Rev.1	Reflection paper on publication of withdrawals of Marketing Authorisation applications for veterinary medicinal products	Adopted, June 2009